SILO Silo Pharma Inc.

Subscribe to $SILO

Silo Pharma Inc.

Subscribe to $SILO

$SILO

Apparel

Consumer Discretionary

IPO Year:

Exchange: NASDAQ

Recent Analyst Ratings for Silo Pharma Inc.

Date	Price Target	Rating	Analyst

See more ratings

Silo Pharma Inc. Press Releases

Fastest customizable press release news feed in the world

View All

Silo Pharma's PTSD Candidate SPC-15 Achieves Positive Safety Milestone, Paving Way for Accelerated Clinical Trials Under 505(b)(2) Pathway

SPC-15's intranasal spray formulation meets safety standards for clinical trial development SARASOTA, FL, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or "the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced positive bioanalytical and safety/toxicology results for its U.S. Food and Drug Administration (FDA)-requested 7-day large animal safety study of its lead asset SPC-15. Silo CEO Eric Weisblum commented, "Overall, we believe the positive results of this study confirm that SPC-15's formulation and spray profile meets the safety standards for clinical trials. While the safety of the oral coun

8/19/25 8:05:00 AM ET

$SILO

Apparel

Consumer Discretionary

Silo Pharma Appoints Crypto Infrastructure Pioneer Corwin Yu to Launch Institutional Bitcoin, Ethereum and Solana Treasury Platform

Targeting Multi-Chain Digital Asset Growth and Decentralized Finance (DeFi) Integration SARASOTA, FL, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO), today announced the launch of a cryptocurrency treasury strategy which is expected to focus on leading digital assets, including Bitcoin, Ethereum, and Solana. The Company intends to make opportunistic purchases of digital currencies following launch and to leverage staking to generate yield while also focusing on capital preservation and token appreciation. Expanded implementation of this strategy is anticipated to be based on available capital and market conditions. Silo has appointed digital asset tech pioneer, Corwin

8/5/25 8:32:00 AM ET

$SILO

Apparel

Consumer Discretionary

Silo Pharma Announces Completion of Dosing in Safety Study of PTSD Drug SPC-15

SARASOTA, FL, July 16, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced completion of dosing in a U.S. Food and Drug Administration (FDA)-requested 7-day safety and toxicology large animal study of its lead asset SPC-15, and bioanalytical and safety/toxicology results for such study are expected within 60 days. "Our novel PTSD drug candidate SPC-15 has already shown strong safety and therapeutic delivery, and we are confident about the final data results from our preclinical discovery program," said Eric Weisblum, CEO of Silo. "We rem

7/16/25 8:45:00 AM ET

$SILO

Apparel

Consumer Discretionary

Silo Pharma Advances PTSD Drug SPC-15 Toward Planned 2025 IND Submission with Pre-Clinical Study Data Expected in Q3 2025

Planned submission of IND application in 2025; Phase 1 clinical trial to follow if IND application approved No new PTSD drug approvals in the U.S. in nearly 25 years; large potential addressable market for SPC-15 worldwide SARASOTA, FL, July 07, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it expects to receive data from the additional preclinical studies of its lead asset SPC-15 within the next 30 to 90 days. SPC-15 is a novel intranasal prophylactic targeting Post-Traumatic Stress Disorder (PTSD). The final drug studies ar

7/7/25 8:15:00 AM ET

$SILO

Apparel

Consumer Discretionary

Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market

Technology Co-Developed by the U.S. Department of Veterans Affairs and Emory University NEW YORK, June 25, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it has entered into a non-binding letter of intent to form a strategic 50:50 joint venture with Hoth Therapeutics, Inc. (NASDAQ:HOTH) to develop and commercialize a potential treatment for obesity and metabolic disease based on technology Hoth has exclusively licensed from the U.S. Department of Veterans Affairs (VA) that was co-developed by the VA and Emory University. The n

6/25/25 8:38:00 AM ET

$HOTH

$SILO

Biotechnology: Pharmaceutical Preparations

Health Care

Apparel

Consumer Discretionary

Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease.

*Hoth Therapeutics and Silo Pharma Launch Joint Venture to Commercialize VA-Invented Obesity Drug Targeting $100B+ Global Market Exclusive License from U.S. Department of Veterans Affairs to Advance GDNF-Based Therapy for Obesity and Fatty Liver Disease NEW YORK, June 25, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH) and Silo Pharma, Inc. (NASDAQ:SILO) today announced the formation of a strategic joint venture to develop and commercialize a first-in-class treatment for obesity and metabolic disease based on technology exclusively licensed from the U.S. Department of Veterans Affairs (VA).

6/25/25 8:27:00 AM ET

$HOTH

$SILO

Biotechnology: Pharmaceutical Preparations

Health Care

Apparel

Consumer Discretionary

Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial Nears

SARASOTA, FL, June 11, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that the U.S. Patent and Trademark Office (USPTO) had issued a Notice of Allowance for U.S. Patent Application No. 17/954,858 (titled "Biomarkers for Efficacy of Prophylactic Treatments Against Stress-Induced Affective Disorders") that Silo licenses from Columbia University. The to-be-issued patent will further strengthen Silo's IP protection for its lead asset, SPC-15, an intranasal treatment targeting post-traumatic stress disorder (PTSD). The patent is expected

6/11/25 9:00:00 AM ET

$SILO

Apparel

Consumer Discretionary

Silo Pharma Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset

SARASOTA, FL, June 05, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that its Board of Directors has approved the purchase of up to $1 million in Bitcoin as a treasury reserve asset. "The addition of Bitcoin to our treasury holdings is a strategic decision aimed at diversifying our assets to include a digital store of value with what we believe has significant upside potential," said Eric Weisblum, CEO of Silo. "Our purchase of Bitcoin is intended to provide a safeguard against inflation and is expected to position Silo to preserv

6/5/25 9:15:00 AM ET

$SILO

Apparel

Consumer Discretionary

Silo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15

SARASOTA, FL, May 21, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it has entered into a service agreement with medical technology provider Resyca BV for a drug-device study of the formulation-specific microchip-based nasal spray system used in its lead asset SPC-15, an intranasal prophylactic treatment for post-traumatic stress disorder (PTSD). "This study is expected to provide the final necessary device data and documentation for SPC-15's IND, which we plan to submit to the FDA this year," said Eric Weisblum, CEO of Silo. "

5/21/25 8:55:00 AM ET

$SILO

Apparel

Consumer Discretionary

Silo Pharma Announces Closing of $2 Million Public Offering

SARASOTA, FL, May 16, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, closed on the previously announced public offering of 3,333,338 shares of common stock (or pre-funded warrants in lieu thereof), together with series A-1 warrants ("Series A-1 Warrants") to purchase up to 3,333,338 shares of common stock and series A-2 warrants ("Series A-2 Warrants") to purchase up to 3,333,338 shares of common stock at a combined public offering price of $0.60 per share (or pre-funded warrant in lieu thereof) and associated Series A-1 Warrant and Series A-2 Warran

5/16/25 4:15:00 PM ET

$SILO

Apparel

Consumer Discretionary

Silo Pharma Inc.

Recent Analyst Ratings for Silo Pharma Inc.

Silo Pharma Inc.

Recent Analyst Ratings for Silo Pharma Inc.

Silo Pharma Inc. Insider Trading

Chief Executive Officer Weisblum Eric bought $4,329 worth of shares (10,000 units at $0.43), increasing direct ownership by 5% to 197,932 units (SEC Form 4)

SEC Form 4 filed by Director Linsley Wayne

SEC Form 4 filed by Director Munoz Kevin

SEC Form 4 filed by Chief Financial Officer Ryweck Daniel E.

SEC Form 4 filed by Chief Executive Officer Weisblum Eric

SEC Form 4 filed by Director Pavell Jeff

CEO and President Weisblum Eric bought $2,097 worth of shares (2,500 units at $0.84), increasing direct ownership by 1% to 187,932 units (SEC Form 4)

CEO and President Weisblum Eric bought $4,625 worth of shares (5,000 units at $0.93), increasing direct ownership by 3% to 185,432 units (SEC Form 4)

CEO and President Weisblum Eric bought $5,533 worth of shares (5,000 units at $1.11), increasing direct ownership by 3% to 180,432 units (SEC Form 4)

Weisblum Eric bought $1,988 worth of shares (1,000 units at $1.99), increasing direct ownership by 0.57% to 175,432 units (SEC Form 4)

Silo Pharma Inc. Press Releases

Silo Pharma's PTSD Candidate SPC-15 Achieves Positive Safety Milestone, Paving Way for Accelerated Clinical Trials Under 505(b)(2) Pathway

Silo Pharma Appoints Crypto Infrastructure Pioneer Corwin Yu to Launch Institutional Bitcoin, Ethereum and Solana Treasury Platform

Silo Pharma Announces Completion of Dosing in Safety Study of PTSD Drug SPC-15

Silo Pharma Advances PTSD Drug SPC-15 Toward Planned 2025 IND Submission with Pre-Clinical Study Data Expected in Q3 2025

Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market

Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease.

Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial Nears

Silo Pharma Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset

Silo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15

Silo Pharma Announces Closing of $2 Million Public Offering

Silo Pharma Inc. SEC Filings

SEC Form 424B5 filed by Silo Pharma Inc.

SEC Form 10-Q filed by Silo Pharma Inc.

Silo Pharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

Silo Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

Silo Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

Silo Pharma Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Silo Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

SEC Form 424B4 filed by Silo Pharma Inc.

SEC Form EFFECT filed by Silo Pharma Inc.

Amendment: SEC Form S-1/A filed by Silo Pharma Inc.

Silo Pharma Inc. Leadership Updates

Silo Pharma Appoints Crypto Infrastructure Pioneer Corwin Yu to Launch Institutional Bitcoin, Ethereum and Solana Treasury Platform

Silo Pharma Inc. Large Ownership Changes

SEC Form SC 13G filed by Silo Pharma Inc.

SEC Form SC 13G filed by Silo Pharma Inc.

SEC Form SC 13G/A filed by Silo Pharma Inc. (Amendment)

SEC Form SC 13G/A filed by Silo Pharma Inc. (Amendment)

Silo Pharma Inc. Insider Purchases

Chief Executive Officer Weisblum Eric bought $4,329 worth of shares (10,000 units at $0.43), increasing direct ownership by 5% to 197,932 units (SEC Form 4)

CEO and President Weisblum Eric bought $2,097 worth of shares (2,500 units at $0.84), increasing direct ownership by 1% to 187,932 units (SEC Form 4)

CEO and President Weisblum Eric bought $4,625 worth of shares (5,000 units at $0.93), increasing direct ownership by 3% to 185,432 units (SEC Form 4)

CEO and President Weisblum Eric bought $5,533 worth of shares (5,000 units at $1.11), increasing direct ownership by 3% to 180,432 units (SEC Form 4)

Weisblum Eric bought $1,988 worth of shares (1,000 units at $1.99), increasing direct ownership by 0.57% to 175,432 units (SEC Form 4)

Weisblum Eric bought $8,713 worth of shares (4,508 units at $1.93), increasing direct ownership by 3% to 174,432 units (SEC Form 4)

Weisblum Eric bought $1,137 worth of shares (700 units at $1.62), increasing direct ownership by 0.41% to 169,924 units (SEC Form 4)

Weisblum Eric bought $1,668 worth of shares (1,100 units at $1.52), increasing direct ownership by 0.65% to 169,224 units (SEC Form 4)

Weisblum Eric bought $1,376 worth of shares (1,000 units at $1.38), increasing direct ownership by 0.60% to 168,124 units (SEC Form 4)

Weisblum Eric bought $3,100 worth of shares (2,000 units at $1.55), increasing direct ownership by 1% to 167,124 units (SEC Form 4)